Summary
After the age of 30, our muscle strength declines by ~14% per decade. In up to 40% of the elderly, this decline culminates in sarcopenia (SP), critically low muscle mass, causing impaired mobility and longer hospitalizations. Muscle decline rates vary greatly between individuals due to genetic and environmental factors. Yet, our lack of insight into these factors impedes developing effective measures against SP.
SP is clinically similar to inclusion body myositis (IBM), the most common myopathy in the elderly, and their molecular phenotypes are very similar. Preliminary data from my host lab, the Laboratory of Integrative Systems Physiology (LISP), show that high-fat diet induces amyloid-containing aggregates in the muscles of aging mice. Such aggregates are hallmarks of muscle proteinopathies such as IBM. Hence, these diseases may be the pathological extremes of natural protein aggregation in the muscle.
LISP recently described the protective, therapeutic role of activating mitochondrial stress responses in aggregation diseases. Activating these pathways prevents aggregate formation in cells, worms and transgenic Alzheimer’s mice. I thus hypothesize that mitochondrial dysfunction worsens the pathology of muscle aggregation diseases and SP.
My project AmyloAge will explore natural aging in muscle in large, genetically diverse populations of worms, mice and humans. I will use my expertise in proteomics to study the evolution of muscle protein composition and find the genetic determinants associated with unhealthy protein aggregation and muscle decline. With my expertise in biostatistics, I will build an analysis pipeline to find the genes and molecular pathways responsible for protein aggregation and metabolic dysfunction in the muscle.
AmyloAge will increase our knowledge of the molecular and physiological variability in muscle aging. This will lay the groundwork for preventive interventions against SP and protein aggregation diseases like IBM.
SP is clinically similar to inclusion body myositis (IBM), the most common myopathy in the elderly, and their molecular phenotypes are very similar. Preliminary data from my host lab, the Laboratory of Integrative Systems Physiology (LISP), show that high-fat diet induces amyloid-containing aggregates in the muscles of aging mice. Such aggregates are hallmarks of muscle proteinopathies such as IBM. Hence, these diseases may be the pathological extremes of natural protein aggregation in the muscle.
LISP recently described the protective, therapeutic role of activating mitochondrial stress responses in aggregation diseases. Activating these pathways prevents aggregate formation in cells, worms and transgenic Alzheimer’s mice. I thus hypothesize that mitochondrial dysfunction worsens the pathology of muscle aggregation diseases and SP.
My project AmyloAge will explore natural aging in muscle in large, genetically diverse populations of worms, mice and humans. I will use my expertise in proteomics to study the evolution of muscle protein composition and find the genetic determinants associated with unhealthy protein aggregation and muscle decline. With my expertise in biostatistics, I will build an analysis pipeline to find the genes and molecular pathways responsible for protein aggregation and metabolic dysfunction in the muscle.
AmyloAge will increase our knowledge of the molecular and physiological variability in muscle aging. This will lay the groundwork for preventive interventions against SP and protein aggregation diseases like IBM.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/896042 |
| Start date: | 01-09-2020 |
| End date: | 31-08-2022 |
| Total budget - Public funding: | 203 149,44 Euro - 203 149,00 Euro |
Cordis data
Original description
After the age of 30, our muscle strength declines by ~14% per decade. In up to 40% of the elderly, this decline culminates in sarcopenia (SP), critically low muscle mass, causing impaired mobility and longer hospitalizations. Muscle decline rates vary greatly between individuals due to genetic and environmental factors. Yet, our lack of insight into these factors impedes developing effective measures against SP.SP is clinically similar to inclusion body myositis (IBM), the most common myopathy in the elderly, and their molecular phenotypes are very similar. Preliminary data from my host lab, the Laboratory of Integrative Systems Physiology (LISP), show that high-fat diet induces amyloid-containing aggregates in the muscles of aging mice. Such aggregates are hallmarks of muscle proteinopathies such as IBM. Hence, these diseases may be the pathological extremes of natural protein aggregation in the muscle.
LISP recently described the protective, therapeutic role of activating mitochondrial stress responses in aggregation diseases. Activating these pathways prevents aggregate formation in cells, worms and transgenic Alzheimer’s mice. I thus hypothesize that mitochondrial dysfunction worsens the pathology of muscle aggregation diseases and SP.
My project AmyloAge will explore natural aging in muscle in large, genetically diverse populations of worms, mice and humans. I will use my expertise in proteomics to study the evolution of muscle protein composition and find the genetic determinants associated with unhealthy protein aggregation and muscle decline. With my expertise in biostatistics, I will build an analysis pipeline to find the genes and molecular pathways responsible for protein aggregation and metabolic dysfunction in the muscle.
AmyloAge will increase our knowledge of the molecular and physiological variability in muscle aging. This will lay the groundwork for preventive interventions against SP and protein aggregation diseases like IBM.
Status
CLOSEDCall topic
MSCA-IF-2019Update Date
28-04-2024
Images
No images available.
Geographical location(s)
